EMA authorization for Reprocyc ParvoFLEX

Boehringer Ingelheim obtains EMA authorization for Reprocyc ® ParvoFLEX, a new porcine parvovirus vaccineReprocyc ® ParvoFLEX is the first subunit porcine parvovirus vaccine obtained through a baculovirus expression systemIt is mixable and can be applied together with Reprocyc PRRS EUVeterinarians and producers can now control two of the most prevalent reproductive diseases in swine herds simultaneously
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news